Outcome of Women With Cervical Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02026648

Enrollment

Registered

2014-01-03

Start date

2014-01-31

Completion date

2016-05-31

Last updated

2016-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Brief summary

Squamous cell carcinoma (SCC) of the cervix has showed a marked decline in developed countries over the past 40 years, however, there has also been an increase in relative and absolute incidence of adenocarcinoma and adenosquamous carcinoma (AC) of the uterine cervix over the same period. Our understanding of the natural history and optimal management of AC is limited. It appears that AC and SCC of the cervix behave differently. They are different in epidemiology, prognostic factors, and patterns of failure after similar treatments. Available data suggest that they may also differ in their response to treatment. We postulate that new treatment strategies specifically tailored to AC should be explored. However, there is few data about outcome of cervical cancer in Taiwan. So we propose this proposal for retrospective analysis of clinicopathological parameters and outcomes in patients of cervical cancer, especially for cervical adenocarcinoma and adenosquamous carcinoma.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Time interval: from 1991 to date. * Comprehensive surgical staging, debulking procedure, radiotherapy or chemotherapy. * All female patients with cervical cancer who underwent treatment for cervical cancer at Far Eastern Memorial Hospital. * All the patients diagnosed as cervical cancer, especially for women with adeno- and adenosquamous carcinoma. * To review: 1. Clinical data: including age at diagnosis, presenting symptoms, gravidity, parity, menstrual history, body mass index, history of diabetes, hypertension, personal history of cancer and staging. 2. Pathologic information: deep stromal invasion, lymph-vascular space invasion, lymph node involvement, parametrium invasion, vaginal cut end and tumor size. 3. Survival data: disease-free and overall survival. 4. Radiation report, Chemotherapy treatment, operation, discharge and admission note.

Exclusion criteria

* Not comprehensive staging/debulking procedure. * Patients who died of postoperative complications within 30 days after surgery were excluded from the survival analysis. * Female minors or disabled persons.

Design outcomes

Primary

Measure	Time frame
Outcome of women with cervical cancer	20 years

Countries

Taiwan

Outcome results